Jiangsu Biostronger Technology Co.,Ltd

 

HGH, Peptides, IGF-1 LR3, EGF, VEGF, Steroids And SARMs powder, Etc.

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsAnti Estrogen Supplements

CAS 82640-04-8 Anti Estrogen Supplements Raloxifene Hydrochloride / Raloxifene HCl

I'm Online Chat Now
Just completed an order with Peter and his service is A+++. I have posted it elsewhere on the board. I did a gh serum test with his gh and it comes back more 30, crazy high score for 10iu.

—— Ricky Rodrig from USA

Was and am VERY, VERY impressed with Peter. Superb communication and overall customer service!! A+++++. will definitely be doing business with you.

—— Trevor Maki from UK

CAS 82640-04-8 Anti Estrogen Supplements Raloxifene Hydrochloride / Raloxifene HCl

CAS 82640-04-8 Anti Estrogen Supplements Raloxifene Hydrochloride / Raloxifene HCl
CAS 82640-04-8 Anti Estrogen Supplements Raloxifene Hydrochloride / Raloxifene HCl

Large Image :  CAS 82640-04-8 Anti Estrogen Supplements Raloxifene Hydrochloride / Raloxifene HCl Get Best Price

Product Details:

Place of Origin: China
Brand Name: SGH
Certification: GMP, ISO9001,BRC,KOSHER
Model Number: 82640-04-8

Payment & Shipping Terms:

Minimum Order Quantity: 10g
Price: Negotiation
Packaging Details: Discreet package or foiled bag or pack as customer's request
Payment Terms: T/T, Western Union, MoneyGram, Bitcoin
Supply Ability: 100kg/Month
Detailed Product Description
CAS NO: 82640-04-8 Synonyms: Raloxifene
Form: Powder Usage: Loss Weight
Color: White Storage: -20C
High Light:

medicine steroids

,

anabolic steroid hormones

CAS 82640-04-8 Anti Estrogen Supplements Raloxifene Hydrochloride / Raloxifene HCl

 

Raloxifene hydrochloride is a second-generation Selective Estrogen Receptor Modulator (SERM) of the benzothiophene family. This drug is similar in effect to tamoxifen, exhibiting estrogen receptor antagonist (blocking) properties in some tissues while acting as an estrogen receptor agonist (activator) in others.

The main point of variation between these two agents is their tissue selectivity. While raloxifene hydrochloride is a strong anti-estrogen in breast and uterine tissues, it appears to be estrogenic in bone. This allows it to protect bone density, mimicking the beneficial effects of endogenous estradiol. This is quite different from tamoxifen, which is anti-estrogenic in both breast and bone.

In a role that was novel for an anti-estrogen, raloxifene hydrochloride was approved by the FDA for the prevention and treatment of osteoporosis in post-menopausal women. It is also being investigated for several other potential uses, including the treatment and prevention of cardiovascular disease, breast cancer, gynecomastia, prostate cancer, acromegaly, and uterine cancer.


Raloxifene Hydrochloride is used to help prevent and treat thinning of the bones (osteoporosis) only in postmenopausal women.

It works like an estrogen to stop the bone loss that can develop in women after menopause, but it does not increase the bone density as much as daily 0.625 mg doses of conjugated estrogens. Raloxifene Hydrochloride will not treat hot flashes of menopause and may cause hot flashes to occur. Also, Raloxifene Hydrochloride does not stimulate the breast or uterus as estrogen does.

Raloxifene Hydrochloride lowers the blood concentrations of total and low-density lipoprotein (LDL) cholesterol, the bad cholesterols, but it does not increase concentrations of high-density lipoprotein (HDL) cholesterol, the good cholesterol, in your blood.

Raloxifene Hydrochloride is also used to lower chances of having invasive breast cancer in postmenopausal women with osteoporosis or at high risk of having invasive breast cancer .
This medicine is available only with your doctor's prescription.

Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although these uses are not included in product labeling, Raloxifene Hydrochloride is used in certain patients with the following medical conditions:

Breast cancer prevention in high-risk women who have already gone through menopause.


Application


May prevent or treat corticosteroid-induced bone loss. American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents or in whom such therapies are contraindicated.


Reduction in the incidence of invasive breast cancer inpostmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial).


Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established. Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. 1 Not indicated for reduction in the risk of noninvasive breast cancer.

 

 

Usage


1. Amino acid, nutrient


2. Labeled , intended for use as an internal standard for the quantification by GC- or LC-mass
spectrometry.


3. A nonsteroidal, selective estrogen receptor modulator (SERM). Antiosteoporotic.

 

Mechanism of Action


Evista (raloxifene hydrochloride) is an estrogen agonist/antagonist, referred to as a selective estrogen receptor modulator (SERM) and belongs to the benzothiophene class of compounds. The biological actions of raloxifene are largely mediated through binding to estrogen receptors.

This binding results in activation of estrogenic pathways in some tissues (agonism) and and the blockade of estrogenic pathways in other tissues (antagonism). The agonistic or antagonistic activity of raloxiffene depends on the extent of recruitment of coactivators and corepressors to estrogen receptor (ER) target gene promotors.

 

 

 

SARM (Raw Powder)
MK-2866 (Ostarine)
Andarine (S4)
GW-501516 (Cardarine)
S-23
LGD-4033 (Ligandrol)
LGD-3303
MK-677 (Ibutamoren)
SR9009
SR9011
RAD140
YK-11
Aicar
Laxogenin
 
 

 

Related products:

Peptides Proteins Steroids Powder
GHRP-2 IGF-1 LR3 17a-Methyl-1-Testosterone
GHRP-6 IGF-1 LR3 Anastrozole (Arimidex)
CJC-1295 with DAC IGF-1 DES Boldenone
CJC-1295 NO DAC Follistatin Boldenone undecylenate (EQ)
HGH176-191 HGH Clomiphene Citrate(Clomid)
PT-141 HCG Tamoxifen Citrate
Thymosin β4 (TB500) EPO Nolvadex
Ipamorelin HMG Sildenafil(Viagra)
Melanotan-II (MT-II)   Tadalafil (Cialis)
Melanotan-I (MT-I) SARM Letrozole (Femara)
PEG-MGF MK-2866 (Ostarine) Exemestane(Aromasin)
MGF Andarine (S4) Formestane
Hexarelin GW-501516 (Cardarine) Mesterolone(Proviron)
Sermorelin S-23 Methandrostenolone (Dianabol)
Triptorelin LGD-4033 (Ligandrol) Methenolone Acetate
Gonadoreline LGD-3303 Methenolone Enanthate
Selank MK-677 (Ibutamoren) Turinabol
BPC-157 SR9009 Nandrolone decanoate
Oxytocin SR9011 Nandrolone phenylpropionate
DSIP RAD140 Oxymetholone (Anadrol)
GHRH YK-11 Stanozolol Coarse (Winstrol)
Tesamorelin Aicar Stanozolol Micronized (Winstrol)
Epitalon Laxogenin Oxandrolone (Anavar)

 

 

 

Contact Details
Jiangsu Biostronger Technology Co.,Ltd

Contact Person: sales

Send your inquiry directly to us